Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres prescribed using the MIRD model for Intrahepatic Cholangiocarcinoma

2021 ◽  
Author(s):  
Ammar Sarwar ◽  
Aamir Ali ◽  
Damir Ljuboja ◽  
Jeffrey L. Weinstein ◽  
Anuradha S. Shenoy-Bhangle ◽  
...  
Keyword(s):  
Intrahepatic Cholangiocarcinoma ◽  
Transarterial Radioembolization ◽  
Resin Microspheres ◽  
Yttrium 90

Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases

2018 ◽  
Vol 29 (6) ◽  
pp. 858-865 ◽  
Author(s):  
Yuki Tomozawa ◽  
Younes Jahangiri ◽  
Priya Pathak ◽  
Kenneth J. Kolbeck ◽  
Ryan C. Schenning ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumor ◽  
Transarterial Radioembolization ◽  
Resin Microspheres ◽  
Yttrium 90

Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma

2018 ◽  
Vol 14 (9) ◽  
pp. 809-818 ◽  
Author(s):  
Luca Filippi ◽  
Orazio Schillaci ◽  
Roberto Cianni ◽  
Oreste Bagni
Keyword(s):  
Intrahepatic Cholangiocarcinoma ◽  
Resin Microspheres ◽  
Yttrium 90

scholarly journals Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma–An Evaluation of Predictors

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5399
Author(s):  
Karolin J. Paprottka ◽  
Franziska Galiè ◽  
Michael Ingrisch ◽  
Tobias Geith ◽  
Harun Ilhan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Confidence Intervals ◽  
Intrahepatic Cholangiocarcinoma ◽  
Predictive Value ◽  
Progression Free Survival ◽  
Tumor Burden ◽  
Free Survival ◽  
Resin Microspheres ◽  
Baseline Characteristics ◽  
Yttrium 90

Trans-arterial radioembolization (TARE) is increasingly evaluated for unresectable intrahepatic cholangiocarcinoma (ICC). Not all ICC patients benefit equally well from TARE. Therefore, we sought to evaluate variables predicting progression-free survival (PFS) and overall survival (OS). Patients with non-resectable ICC underwent TARE and were treated with 90Y resin microspheres. Baseline characteristics, biochemical/clinical toxicities, and response were examined for impact on PFS and OS. A total of 103 treatments were administered to 73 patients without major complications or toxicity. Mean OS was 18.9 months (95% confidence intervals (CI); 13.9–23.9 months). Mean and median PFS were 10.1 months (95% CI; 7.9–12.2) and 6.4 months (95% CI; 5.20–7.61), respectively. Median OS and PFS were significantly prolonged in patients with baseline cholinesterase (CHE) ≥4.62 kU/L (OS: 14.0 vs. 5.5 months; PFS: 6.9 vs. 3.2 months; p < 0.001). Patients with a tumor burden ≤25% had a significantly longer OS (15.2 vs. 6.6 months; p = 0.036). Median PFS was significantly longer for patients with multiple TARE cycles (24.4 vs. 5.8 months; p = 0.04). TARE is a considerable and safe option for unresectable ICC. CA-19-9, CHE, and tumor burden have predictive value for survival in patients treated with TARE. Multiple TARE treatments might further improve survival; this has to be confirmed by further studies.

Radioembolization for Cholangiocarcinoma

2021 ◽  
Author(s):  
Aamir Ali ◽  
Komal Manzoor ◽  
Jeffrey L. Weinstein ◽  
Salomao Faintuch ◽  
Muneeb Ahmed ◽  
...  
Keyword(s):  
Intrahepatic Cholangiocarcinoma ◽  
Systemic Chemotherapy ◽  
Standard Of Care ◽  
Hepatic Malignancy ◽  
Current Standard ◽  
Transarterial Radioembolization ◽  
Total Cancer ◽  
Localized Disease ◽  
Yttrium 90

AbstractCholangiocarcinoma is the second most common primary hepatic malignancy which accounts for 13% of total cancer mortality worldwide. Surgical resection is the only curative treatment for localized disease; however, the majority of patients present when the tumor is unresectable. The incidence of the intrahepatic subtype of cholangiocarcinoma is increasing worldwide. Current standard of care in patients with unresectable intrahepatic cholangiocarcinoma is systemic chemotherapy; however, yttrium-90 transarterial radioembolization (Y90-TARE) is under investigation for the treatment of intrahepatic cholangiocarcinoma with promising trials and published clinical experience. This review critically evaluates the role of Y90-TARE in the management of intrahepatic cholangiocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document